Welcome to our dedicated page for Innovage Holding SEC filings (Ticker: INNV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing InnovAge Holding Corp’s SEC disclosures can feel like decoding a medical chart: capitated revenue calculations, PACE enrollment data, CMS audit outcomes, and risk-adjustment assumptions are scattered across hundreds of pages. Missing a single footnote could hide how InnovAge controls hospitalizations or meets quality benchmarks—that’s the challenge.
Stock Titan solves it with AI-powered summaries that translate dense language into plain English and point you to the exact table that matters. Whether you need the InnovAge quarterly earnings report 10-Q filing for segment margins or real-time alerts on InnovAge insider trading Form 4 transactions, every document lands here seconds after EDGAR posts. Our system flags material developments, highlights PACE census trends, and even compares medical cost ratios quarter over quarter.
Here’s what you can track in one place:
- "InnovAge annual report 10-K simplified"—discover capitation risk factors and state licensing updates.
- "InnovAge Form 4 insider transactions real-time"—watch executive stock moves alongside quality-score milestones.
- "InnovAge proxy statement executive compensation"—see how pay aligns with clinical outcomes.
- "InnovAge 8-K material events explained"—from CMS audit findings to leadership changes.
Want deeper context? Our AI offers InnovAge earnings report filing analysis and tools for understanding InnovAge SEC documents with AI. That means quicker due diligence, clearer investment theses, and fewer surprises when material events surface.
Stop scrolling through PDFs and start focusing on decisions. Every InnovAge executive stock transactions Form 4, each risk disclosure, every performance metric—clarified, searchable, and always current.
InnovAge Holding Corp. operates the largest PACE platform by participants, serving ~7,740 participants through 20 centers across six states and managing care under fully capitated contracts. The company receives virtually all revenue from PACE (99.8%), giving it recurring per-member payments and visibility into revenue; InnovAge estimates an average annual revenue opportunity of $115,000 per participant (or $9,600 PMPM) and reports an average Medicare RAF score of 2.42, reflecting a higher-acuity population. Clinical outcomes and operations highlights include approximately 93% of participants living safely at home and reported lower readmission rates versus comparable populations. Key financial and legal items disclosed include $60.0 million principal term loan, a $2.2 million convertible term loan classified as held for sale, and a securities class action settlement of $27.0 million with the company’s net share of $10.1 million. The filing emphasizes material regulatory, compliance and litigation risks, concentrated payor dependence on Medicare and Medicaid, cybersecurity and data privacy exposures, and ongoing investments and transformation initiatives that may affect future profitability.
Blair P. T. Blair, Chief Executive Officer and director of InnovAge Holding Corp. (INNV), reported a routine disposition of company stock tied to equity vesting. On 09/01/2025 the reporting person had 5,056 shares withheld at a price of $3.83 to satisfy tax obligations related to the vesting and settlement of restricted stock units. After the withholding, the reporting person beneficially owned 714,126 shares of common stock. The filing indicates this was a tax-withholding action rather than an open-market sale.
Nicole D'Amato, Chief Legal Officer of InnovAge Holding Corp. (INNV), reported a transaction dated 08/15/2025 on a Form 4. The filing discloses 14,303 shares of Common Stock were disposed of at $3.43 per share pursuant to tax withholding related to the vesting and settlement of restricted stock units. After the withholding disposition, the reporting person beneficially owned 319,807 shares. The Form 4 was signed on 08/18/2025. The filing explicitly states the shares were withheld to satisfy tax obligations and does not indicate an open-market sale or change in control.
FAQ
What is the current stock price of Innovage Holding (INNV)?
What is the market cap of Innovage Holding (INNV)?
